|
|
Latest Headlines
Xcelience and IriSys business alliance agreement strengthens regional access to CMC/Regulatory expertise
More...
| Xcelience Adds Piccola B10 Minipress for GMP Tablet Formulation Development in Experimental Area
More...
| Xcelience and Penn Pharma Form a Joint Venture to Provide API Into Capsule Services in Europe and Asia Pacific Markets
More...
|
|
|
|
|
|
|
News
|
|
|
|
Xcelience Vice President’s distinguished record earns him recognition.
|
|
November 6, 2006 (San Antonio, TX) - Randall H. Guthrie, Vice President of Xcelience, LLC, was awarded for his longevity and dedication to the American Association of Pharmaceutical Scientists (AAPS) by receiving a Presidential Citation at this year’s 20th anniversary meeting. The citation recognizes Guthrie’s active participation in the past 20 AAPS Meetings and Expositions.
|
|
Guthrie has over 29 years of experience in the Pharmaceutical Service Industry. In his role as Vice President at Xcelience, he oversees all Business Development and Marketing. Prior to the launch of Xcelience, he led MDS Pharma Services and legacy Phoenix International Life Sciences, as Vice President of Strategic Development and Global Vice President of Business Development. Having hands on experience in MDS’ business segments and several other Pharmaceutical based providers; Guthrie is well versed in the drug development continuum and the needs and requirements of the formulation process.
|
|
Xcelience is the premier source for unsurpassed quality in drug discovery. The company brings together the industry’s most experienced and talented scientists, consistently and efficiently moving compounds through the research and development stages to market.
|
|
Since 1997, the Tampa-based laboratory has been developing formulations for clients throughout the country. Our unique corporate structure creates project teams which work intensively with each client, becoming an extension of their own organization. Xcelience range of services include formulation development, analytical methods development and their qualifications and clinical trial material production.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|